Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Eli Lilly and Company rose $0.74 (1.5%) to $51.23 on average volume. Throughout the day, 5,094,675 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6,159,700 shares. The stock ranged in a price between $50.40-$51.24 after having opened the day at $50.52 as compared to the previous trading day's close of $50.49. Other companies within the Drugs industry that increased today were: Ariad Pharmaceuticals ( ARIA), up 35.5%, Galena Biopharma ( GALE), up 14.6%, POZEN ( POZN), up 14.6% and Cardiome Pharma Corporation ( CRME), up 14.4%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.1 billion and is part of the health care sector. The company has a P/E ratio of 11.6, below the S&P 500 P/E ratio of 17.7. Shares are up 2.4% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 38.6%, Conatus Pharmaceuticals ( CNAT), down 11.9%, Amarin Corporation ( AMRN), down 11.5% and Oncolytics Biotech ( ONCY), down 8.3% , were all laggards within the drugs industry with Jazz Pharmaceuticals ( JAZZ) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief